Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neu… Read more
Euroespes S.A. - Asset Resilience Ratio
Euroespes S.A. (EEP) has an Asset Resilience Ratio of 8.53% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Euroespes S.A.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Euroespes S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €971.10K | 8.5% |
| Short-term Investments | €2.65K | 0.02% |
| Total Liquid Assets | €973.75K | 8.53% |
Asset Resilience Insights
- Limited Liquidity: Euroespes S.A. maintains only 8.53% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Euroespes S.A. Industry Peers by Asset Resilience Ratio
Compare Euroespes S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Euroespes S.A. (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Euroespes S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | €370.00 | €6.94 Million | -0.03pp |
| 2023-12-31 | 0.03% | €2.47K | €7.93 Million | -8.50pp |
| 2022-12-31 | 8.53% | €973.75K | €11.42 Million | -7.68pp |
| 2021-12-31 | 16.21% | €1.99 Million | €12.25 Million | -2.95pp |
| 2020-12-31 | 19.16% | €2.24 Million | €11.70 Million | +18.98pp |
| 2019-12-31 | 0.18% | €20.46K | €11.37 Million | +0.05pp |
| 2018-12-31 | 0.13% | €16.85K | €12.76 Million | -0.05pp |
| 2017-12-31 | 0.18% | €16.76K | €9.35 Million | +0.17pp |
| 2016-12-31 | 0.00% | €436.97 | €8.90 Million | -0.06pp |
| 2015-12-31 | 0.06% | €4.28K | €6.73 Million | -0.04pp |
| 2014-12-31 | 0.10% | €6.38K | €6.33 Million | -1.79pp |
| 2010-12-31 | 1.89% | €96.76K | €5.11 Million | -- |